Details of the Drug

General Information of Drug (ID: DM63QS9)

• Drug Name: Nystatin
• Synonyms: Biofanal; Comycin; Diastatin; Fungicidin; Herniocid; Korostatin; Moronal; Myconystatin; Mycostatin; Mykinac; Mykostatyna; Nilstat; Nistatin; Nistatina; Nyamyc; Nyotran; Nystaform; Nystan; Nystatine; Nystatinum; Nystatyna; Nystavescent; Nystex; Nystop; Stamicin; Stamycin; Terrastatin; Candex Lotion; Mycostatin Pastilles; Nystatin A; Nystatin G; Nystatin preparation; Nystatyna [Polish]; Zydin E; Barstatin 100; Mycostatin 20; Nystatin A1; Nystatin A2; Nystatin A3; Animax (TN); Candio-hermal; Flagystatin II (TN); Infestat (TN); Korostatin (TN); Lystin (TN); Moronal (antibiotic); Mycostatin (TN); Mykacet (TN); Mykinac (TN); Mytrex (TN); Nidoflor (TN); Nilstat (TN); Nistatina (TN); Nistatina [INN-Spanish]; Nysert (TN);Nystaform (TN); Nystalocal (TN); Nystamont (TN); Nystan (TN); Nystatin LF (liposome); Nystatine [INN-French]; Nystatinum [INN-Latin]; Nystex (TN); Nystop (TN); O-V Statin; Myco-Triacet II (TN); Mycolog-II (TN); Nystatin A1, A2, A3 complex; Nystatin [INN:BAN:JAN]; (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(3-amino-3,6-dideoxy-a-D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid; (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(3-amino-3,6-dideoxy-alpha-D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid; (4E,6E,8E,10E,14E,16E)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid; (4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,35S)-3-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid; (4E,6E,8E,10E,14E,16E,18S,19R,21S,35S)-3-[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Cutaneous candidiasis	1F23.14	Approved	[1]
Fungal infection	1F29-1F2F	Approved	[2]
Mycoses	1F2Z	Approved	[1]
Oral candidiasis	1F23.0	Approved	[1]
Autoimmune polyendocrine syndrome type 1	N.A.	Investigative	[1]

• Therapeutic Class: Antifungal Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 3:
  Molecular Weight (mw); 926.1
  Logarithm of the Partition Coefficient (xlogp); -0.2
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 12
  Hydrogen Bond Acceptor Count (hbondacc); 18
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
  Metabolism: The drug is not metabolised [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 4 mg/mL [3]
• Chemical Identifiers:
  Formula: C47H75NO17
  IUPAC Name: (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid
  Canonical SMILES: C[C@H]1/C=C/C=C/CC/C=C/C=C/C=C/C=C/C(CC2C(C(C[C@](O2)(CC(C(CCC(CC(CC(CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O
  InChI: InChI=1S/C47H75NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-36(53)35(52)20-19-31(49)21-32(50)22-33(51)23-39(55)62-29(3)28(2)42(27)56/h5-6,8,10-18,27-38,40-44,46,49-54,56-58,61H,7,9,19-26,48H2,1-4H3,(H,59,60)/b6-5+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31?,32?,33?,34?,35?,36?,37?,38?,40?,41-,42+,43+,44-,46+,47+/m0/s1
  InChIKey: VQOXZBDYSJBXMA-RKEBNKJGSA-N
• Cross-matching ID:
  PubChem CID: 6433272
  ChEBI ID: CHEBI:473992
  CAS Number: 1400-61-9
  DrugBank ID: DB00646
  TTD ID: D08XAC
  VARIDT ID: DR00957
  ACDINA ID: D00481
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fungal Cell membrane ergosterol (Fung CME)	TTQKWA4	NOUNIPROTAC	Modulator	[5]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Quinoline yellow WS	E00309	24671	Colorant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium hydrogenphosphate	E00294	24441	Diluent
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Water	E00035	962	Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Nystatin 500000 unt tablet	500000 unt	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Nystatin FDA Label
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 062124.
• [3] BDDCS applied to over 900 drugs
• [4] FDA Approved Drug Products: Nystatin oral suspension
• [5] Cholesterol and Ergosterol Influence Nystatin Surface Aggregation: Relation to Pore Formation